New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy

Long, Jaclyn; Ryan, Kevin M.

doi:10.1038/onc.2012.7

Cited by 188 publications

(159 citation statements)

References 176 publications

(210 reference statements)

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Here, we found that the promoter region of miR-200c was hypermethylated in renal carcinoma cell lines treated with sorafenib or imatinib than control, suggesting epigenetic mechanisms might be also involved in ccRCC treatment-resistant. We Heme oxygenase-1 (HO1), an anti-apoptotic gene, was involved in imatinib resistance in cancers [19] and the regulation of autophagy [20]. Mechanically, HO-1 transcriptionally involved in Beclin-1 and Bcl-2 signaling pathway, which has been reported essential for tumor growth and autophagy [21].…”

Section: Discussionmentioning

confidence: 99%

MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1

Gao¹,

Peng²,

Peng³

2014

neo

View full text Add to dashboard Cite

Clear-cell renal cell carcinoma is a highly treatment-resistant tumor type. Heme oxygenase-1 plays an anti-apoptotic role in cancer chemotherapeutic inducing tumor-progression. The miR-200 family was involved in the process of mesenchymal-epithelial transition (MET) during renal development. In the present study, we demonstrated the regulatory relationship between miR-200c and HO-1. We provided evidences to elucidate that miR-200c could sensitize ccRCC cells to sorafenib or imatinib to inhibit cell proliferation, at least partly by targeting HO-1. Moreover, the correlation between miR-200c and HO-1 expression level and drug resistance in ccRCC was also determined. Combined application with chemotherapeutic drugs, miR-200c, a HO-1 inhibitor, may enhance the efficiency of therapy by promoting both apoptosis and autophagy.

show abstract

Section: Discussionmentioning

confidence: 99%

MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1

Gao¹,

Peng²,

Peng³

2014

neo

View full text Add to dashboard Cite

show abstract

“…Subsequently, AIF translocates to the nucleus and provokes chromatin condensation and DNA fragmentation [77]. Necroptosis or regulated necrosis also involves PARP activation [78]. Therefore, PARP can participate in different types of cell death and it is not exclusive of apoptosis, as previously thought.…”

Section: Parp Proteolysis As An Indicator Of Cell Deathmentioning

confidence: 81%

“…A novel death regulation platform named ripoptosome has recently been described. Unlike complex II, the ripoptosome forms independently of death receptors, is activated by genotoxic stress or IAP antagonists and is tightly regulated by IAPs (ciAP1, cIAP2, xIAP) or cellular FLICE-like inhibitory protein (FLIP), a catalytically inactive homologue of caspase-8 [78,90,91]. The executioner mechanisms of necroptosis are unclear.…”

Section: Necroptosismentioning

confidence: 99%

See 1 more Smart Citation

Cell Death and Cancer, Novel Therapeutic Strategies

Grasso¹,

Menéndez-Gutierrez²,

Carrasco‐García³

et al. 2012

Apoptosis and Medicine

View full text Add to dashboard Cite

“…Cancer is a multifactoral disease, with a consequence of the unusual mechanisms of genetic, metabolic or biochemical factors, which basically spoil the controlled proliferation and/or apoptosis mechanism of the cells [1]. The unlimited ability of proliferation, the developed resistance against apoptotic signals, the capability of invasion, metastasis and angiogenesis, abnormal activity of energy metabolism and the defence against immune attack are the hallmarks of cancer [2,3].…”

Section: Introductionmentioning

confidence: 99%

Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells

et al. 2015

View full text Add to dashboard Cite

Multiple myeloma is of great concern since existing therapies are unable to cure this clinical condition. Alternative therapeutic approaches are mandatory, and the use of plant extracts is considered interesting. Punica granatum and its derived products were suggested as potential anticancer agents due to the presence of bioactive compounds. Thus, polypenolic-rich extracts of the non-edible parts of P. granatum were investigated for their antiproliferative and apoptotic effects on U266 multiple myeloma cells. We demonstrated that there were dose-dependent decreases in the proliferation of U266 cells in response to P. granatum extracts. Also, exposure to the extracts triggered apoptosis with significant increases in loss of mitochondrial membrane potential in U266 cells exposed to the leaves and stem extracts, while the flower extract resulted in slight increases in loss of MMP. These results were confirmed by Annexin-V analysis. These results documented the cytotoxic and apoptotic effects of P. granatum extracts on human U266 multiple myeloma cells via disruption of mitochondrial membrane potential and increasing cell cycle arrest. The data suggest that the extracts can be envisaged in cancer chemoprevention and call for further exploration into the potential application of these plant parts.

show abstract

New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy

Cited by 188 publications

References 176 publications

MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1

MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1

Cell Death and Cancer, Novel Therapeutic Strategies

Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells

Contact Info

Product

Resources

About